Physician profile
Anna Melnikoff
NPI 1083078307
$584.28
in general payments reported to CMS, 2019-2025
12 companies · $30.63 in 2025
The $30.63 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.86 · 2021: $254 · 2022: $85.58 · 2023: $74.35 · 2024: $127 · 2025: $30.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.83 | 2021-2025 | |
| Evofem Biosciences, INC. | $126.03 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $82.32 | 2024 | Myfembree |
| Hologic Sales and Service, LLC | $67.62 | 2021-2023 | Aptima |
| Amgen INC. | $38.48 | 2020-2022 | |
| Astellas Pharma US INC | $30.40 | 2022-2025 | Veozah |
| Organon LLC | $19.05 | 2023 | Nexplanon |
| Agile Therapeutics, INC. | $18.87 | 2021 | |
| Exeltis, USA INC. | $15.26 | 2024 | Slynd |
| Sage Therapeutics, LLC | $14.76 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.94 | 2023 | |
| Becton, Dickinson and Company | $12.72 | 2023 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Melnikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.